Claim OwnershipPharma and BioTech Daily
Subscribed: 111Played: 1,504
Subscribe
© 2026 Pharma and BioTech Daily
Description
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
186 Episodes
Reverse
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant advancements and trends shaping the industry landscape, offering insights into how companies are navigating scientific, regulatory, and market challenges.The pharmaceutical and biotech sectors are in a dynamic period marked by substantial scientific advancements and strategic developments. Among the key players, S...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a whirlwind of activity in the industry, where scientific breakthroughs, regulatory shifts, and strategic collaborations are all reshaping the future of healthcare.Let's start with a look at the ongoing efforts by the Trump administration to negotiate Medicare drug prices under the Inflation Reduction Act. This initiative is set to impac...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore a landscape marked by dynamic shifts and groundbreaking advancements in the industry.The European Union has recently taken a significant step forward by eliminating pharmaceutical export tariffs through a comprehensive free trade agreement with India. This landmark deal, nearly two decades in the making, is a strategic response to the turbulenc...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into the multitude of changes and advancements sweeping across the industry, each with profound implications for drug development, patient care, and market dynamics.The pharmaceutical landscape continues to transform as companies like Daiichi Sankyo make significant progress with antibody-drug conjugates (ADCs). Their collaboration with AstraZ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by significant scientific advancements, regulatory challenges, and strategic investments that are shaping the future of healthcare.Let's begin with Moderna's recent decision to halt its late-stage vaccine trials, a move reflective of a broader trend of vaccine hesitancy in the United States. Moderna's CEO Stéphane Bancel p...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of remarkable advancements and strategic collaborations in the industry, showcasing a dynamic period of innovation and regulatory evolution.Corcept Therapeutics has celebrated a significant win with their Phase 3 trial for relacorilant targeting ovarian cancer, revealing improved overall survival rates. This marks a potential rebo...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're delving into the dynamic landscape of scientific breakthroughs, regulatory shifts, and strategic business maneuvers that are shaping the future of healthcare.The pharmaceutical industry is currently abuzz with discussions surrounding Pfizer's leadership, which has taken a firm stance against anti-vaccine narratives, particularly those propagated by ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest transformative movements within this dynamic arena, focusing on pivotal acquisitions, technological integrations, and regulatory updates shaping the future of healthcare solutions.Starting with strategic corporate maneuvers, Pfizer recently divested its 11.7% stake in GSK's ViiV Healthcare, a prominent player in HIV treatments. Th...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant events shaping the industry, from innovative drug formulations and regulatory challenges to the dynamic IPO landscape and clinical trial outcomes.Starting with Novo Nordisk, their oral formulation of Wegovy is witnessing substantial uptake, showcasing a strong demand for novel obesity treatments. This rapid adopt...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic phase shaping the industry, marked by scientific advancements, regulatory changes, and strategic shifts within major companies.Teva Pharmaceuticals is making significant strides under the leadership of CEO Richard Francis. The company is transitioning from its traditional focus on generic drugs to a more innovative biopharmaceutica...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest innovations, strategic shifts, and regulatory updates shaping the industry.Johnson & Johnson's Tecvayli, a promising monotherapy for multiple myeloma, has shown remarkable efficacy in clinical trials. By reducing the risk of disease progression or death by 71% among patients resistant to anti-CD38 therapies, Tecvayli is settin...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a landscape marked by rapid transformations and strategic maneuvers that are reshaping the industry.Novo Nordisk is at a pivotal point under the leadership of CEO Maziar Mike Doustdar. The company is navigating a significant transition, focusing on reclaiming its leadership in the glucagon-like peptide-1 (GLP-1) market. This is crucial as GL...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. This morning, we're diving into a series of fascinating updates that underline the vibrant and ever-changing landscape of our industry.The J.P. Morgan Healthcare Conference recently set the stage for some intriguing discussions, particularly from Novo Nordisk. The company is diversifying its metabolic drug development portfolio by exploring innovative avenues, r...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant events and trends reshaping the industry landscape as we approach 2026. The pharmaceutical and biotech sectors are navigating a transformative period marked by scientific advancements, evolving regulatory frameworks, and strategic partnerships.Starting with a shift towards bolstering drug pipelines, mergers and ac...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative updates reshaping drug development and patient care across the globe.Starting with a major collaboration between Roche and Medilink Therapeutics that has captured industry attention. Roche is making a strategic move by committing $570 million to partner on an antibody-drug conjugate, or ADC, targeting the B7-H3 imm...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.The industry continues to navigate a dynamic landscape marked by significant scientific advancements, regulatory changes, and strategic shifts. Eli Lilly's acquisition of Ventyx Biosciences for $1.2 billion underscores Lilly's commitment to expanding its portfolio in inflammation-related therapeutics, particularly following promising readouts in Parkinson's and c...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic movements shaping the future of healthcare.The pharmaceutical and biotech sectors are undergoing significant transformations, driven by scientific breakthroughs, regulatory developments, and strategic shifts. At the forefront is Eli Lilly's impressive lineup of investigational cardiometab...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we're diving into a landscape rich with scientific advancements, strategic industry shifts, and regulatory developments that are shaping the future of healthcare.Let's start with AstraZeneca's recent success in the lupus treatment field. Their Phase 3 clinical trial for a self-administered subcutaneous form of Saphnelo marks a significant milestone. This n...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. As we delve into the year 2025, it's clear that the pharmaceutical and biotech industries have been navigating a complex landscape filled with both challenges and remarkable advancements. Despite regulatory uncertainties and broader economic fluctuations, the FDA approved 55 new treatments and vaccines this year. Although this figure represents a slight decline ...
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events that are shaping the landscape of this dynamic industry. The ever-evolving arena of drug approvals, regulatory challenges, and strategic shifts continues to captivate stakeholders across the globe.Sanofi's recent acquisition of Dynavax for $2.2 billion illustrates a prevailing trend within the sector—mergers an...
Comments
Download from Google Play
Download from App Store
United States